Hina Jayantilal Shah, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lutetium | 2 | 2023 | 32 | 0.940 |
Why?
|
Receptors, Somatostatin | 1 | 2022 | 129 | 0.780 |
Why?
|
Nuclear Medicine | 1 | 2024 | 233 | 0.760 |
Why?
|
Gastric Emptying | 1 | 2022 | 233 | 0.740 |
Why?
|
Mouth Neoplasms | 2 | 2022 | 601 | 0.690 |
Why?
|
Radiopharmaceuticals | 6 | 2024 | 2658 | 0.540 |
Why?
|
Epidermal Cyst | 1 | 2014 | 62 | 0.460 |
Why?
|
Pineal Gland | 1 | 2014 | 165 | 0.440 |
Why?
|
Thyroid Neoplasms | 1 | 2024 | 2274 | 0.370 |
Why?
|
Lymph Nodes | 1 | 2022 | 3465 | 0.360 |
Why?
|
Positron-Emission Tomography | 6 | 2022 | 6259 | 0.360 |
Why?
|
Head and Neck Neoplasms | 1 | 2022 | 2712 | 0.310 |
Why?
|
Radionuclide Imaging | 2 | 2022 | 2027 | 0.310 |
Why?
|
Fluorodeoxyglucose F18 | 4 | 2022 | 2013 | 0.290 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 1377 | 0.290 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2014 | 1379 | 0.280 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2022 | 4029 | 0.270 |
Why?
|
Brain Diseases | 1 | 2014 | 1554 | 0.250 |
Why?
|
Dipeptides | 2 | 2023 | 409 | 0.230 |
Why?
|
Prostate-Specific Antigen | 2 | 2023 | 2458 | 0.220 |
Why?
|
Axilla | 2 | 2022 | 588 | 0.210 |
Why?
|
Adrenocortical Carcinoma | 1 | 2022 | 88 | 0.200 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2022 | 162 | 0.190 |
Why?
|
Urea | 1 | 2023 | 449 | 0.190 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2022 | 627 | 0.180 |
Why?
|
Prostatic Neoplasms | 1 | 2023 | 11039 | 0.180 |
Why?
|
Taxoids | 1 | 2022 | 665 | 0.170 |
Why?
|
Mutagenesis | 1 | 2022 | 1263 | 0.160 |
Why?
|
Lysine | 1 | 2023 | 1008 | 0.160 |
Why?
|
Neoplasms | 3 | 2022 | 21596 | 0.160 |
Why?
|
Endocrine System | 1 | 2018 | 113 | 0.150 |
Why?
|
Inflammatory Breast Neoplasms | 1 | 2018 | 137 | 0.150 |
Why?
|
Endocrine System Diseases | 1 | 2018 | 248 | 0.130 |
Why?
|
Eating | 1 | 2022 | 1535 | 0.130 |
Why?
|
Glucose | 3 | 2022 | 4391 | 0.120 |
Why?
|
Immunotherapy | 2 | 2022 | 4414 | 0.120 |
Why?
|
Tomography, Emission-Computed | 1 | 2014 | 1144 | 0.090 |
Why?
|
Humans | 17 | 2024 | 742088 | 0.090 |
Why?
|
Epithelial Cells | 1 | 2022 | 3678 | 0.090 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 1618 | 0.080 |
Why?
|
Lymphoma | 1 | 2017 | 1873 | 0.080 |
Why?
|
Male | 8 | 2023 | 349538 | 0.070 |
Why?
|
Huntington Disease | 1 | 2013 | 1111 | 0.070 |
Why?
|
Retrospective Studies | 4 | 2022 | 77098 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 9941 | 0.070 |
Why?
|
Heterocyclic Compounds, 1-Ring | 1 | 2023 | 65 | 0.050 |
Why?
|
Uracil-DNA Glycosidase | 1 | 2022 | 31 | 0.050 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2014 | 2736 | 0.050 |
Why?
|
Treatment Outcome | 3 | 2022 | 62966 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11472 | 0.040 |
Why?
|
DNA-Directed DNA Polymerase | 1 | 2022 | 484 | 0.040 |
Why?
|
Neoadjuvant Therapy | 2 | 2020 | 2721 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2017 | 9185 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2017 | 35342 | 0.040 |
Why?
|
Gonads | 1 | 2018 | 107 | 0.040 |
Why?
|
Adult | 4 | 2022 | 213712 | 0.040 |
Why?
|
Middle Aged | 4 | 2022 | 213127 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2017 | 20086 | 0.030 |
Why?
|
Adrenal Glands | 1 | 2018 | 547 | 0.030 |
Why?
|
Pituitary Gland | 1 | 2018 | 665 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2018 | 13655 | 0.030 |
Why?
|
Gene Deletion | 1 | 2022 | 2751 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2018 | 1248 | 0.030 |
Why?
|
Transplantation, Autologous | 1 | 2017 | 2123 | 0.030 |
Why?
|
Islets of Langerhans | 1 | 2018 | 1351 | 0.020 |
Why?
|
Thyroid Gland | 1 | 2018 | 1172 | 0.020 |
Why?
|
Female | 4 | 2020 | 379592 | 0.020 |
Why?
|
Mastectomy | 1 | 2018 | 1789 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3471 | 0.020 |
Why?
|
Prognosis | 2 | 2022 | 29010 | 0.020 |
Why?
|
Genome, Human | 1 | 2022 | 4420 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 13921 | 0.020 |
Why?
|
Risk | 1 | 2018 | 9679 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2022 | 16665 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10248 | 0.020 |
Why?
|
Aged | 2 | 2020 | 162944 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2017 | 39004 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2020 | 57683 | 0.010 |
Why?
|
United States | 1 | 2023 | 69693 | 0.010 |
Why?
|
Child | 1 | 2013 | 77478 | 0.000 |
Why?
|